Prevalence and Risk Factors for Pain and Related Adverse Reactions Among Breast Cancer Survivors on Aromatase Inhibitors

Recruiting

• Conditions: Breast Cancer; Aromatase Inhibitors; Pain; Anxiety; Endocrine Therapy; Depression; Sleep
• Interventions: Other: No intervention

• Registration Number: NCT05628077
• Lead Sponsor: Peking University People's Hospital

Brief Summary

We obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-11-16
• Study First Submitted QC: 2022-11-16
• Study First Posted: 2022-11-28
• Study Start: 2022-12-30
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-05
• Last Update Posted: 2023-03-07
• Primary Completion: 2023-03-20
• Study Completion: 2023-04-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 1200

Inclusion Criteria

• Breast cancer survivors on aromatase inhibitors

Exclusion Criteria

• Advanced breast cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
NO PAIN	No intervention	-
PAIN	No intervention	-

Primary Outcome Measures

Name	Time	Method
Prevalence and risk factors for pain and related adverse reactions among breast cancer survivors on aromatase inhibitors	2022-10 ---2023-03

Trial Locations

Locations (1)

Peking University People'S Hospital; 🇨🇳 Beijing, China